Posted On: 03 Sep 2026
HaemaLogiX has treated the first patient with its KMCAR T-cell therapy as part of the Phase I KOALA clinical trial for relapsed or refractory kappa-restricted multiple myeloma.
The trial is being conducted at the Peter MacCallum Cancer Centre in Australia.
The treatment was well tolerated and no serious adverse events were reported. A second patient has been enrolled and is expected to receive treatment at a higher dose in the near future.
The study represents the first time KMCAR T-cell immunotherapy has been administered to humans. The therapy targets the Kappa Myeloma Antigen (KMA), which is found only on malignant plasma cells.